EGFR and breast carcinoma: A study investigating the role of the G protein-coupled estrogen receptor (GPER) in palbociclib resistance in breast cancer cells revealed that ER-alpha underexpression, combined with GPER overexpression, was driven by EGFR interacting with the GPER promoter region.